Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Soligenix Inc (SNGX)

$1.24 0.00 (0.00%)

16:00 EST SNGX Stock Quote Delayed 15 Minutes

Volume:

Previous Close $1.24

Market Cap 20.48M

PE Ratio -1.12

EPS -1.11

Volume (Avg. Vol.) 270,700

Day's Range 1.15 - 1.32

52-Week Range 0.65 - 1.39

Dividend & Yield N/A (N/A)

SNGX Stock Predictions, Articles, and Soligenix Inc News

From the Web

Soligenix initiates clinical trial of heat stable ricin toxin vaccine

From Seeking Alpha Dec 12, 2019

Soligenix (NASDAQ:SNGX) has opened Phase 1C study to evaluate the safety and immunogenicity of RiVax in healthy, normal adults, followed by a 6-month follow-up period.The study is expected to enroll 8

Soligenix (SNGX) Receives a Buy from Maxim Group

From Analyst Ratings Dec 4, 2019

Maxim Group analyst Jason McCarthy maintained a Buy rating on Soligenix (SNGX – Research Report) yesterday and set a price target of $4.00. The company’s shares closed last Monday at $1.01. According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -20.1% and a

NetworkNewsBreaks – Soligenix, Inc. (NASDAQ: SNGX) Completes Enrollment in Pivotal Phase 3 SGX301 Clinical Trial in Treatment of Cutaneous T-cell Lymphoma

From NetworkNewsWire Dec 4, 2019

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today completion of patient enrollment in its Phase 3 “Fluorescent Light Activated Synthetic Hypericin” (“FLASH”) study for SGX301 (“synthetic hypericin”) in the treatment of cutaneous T-cell lymphoma (“CTCL”). According to […]

We’re Keeping An Eye On Soligenix’s (NASDAQ:SNGX) Cash Burn Rate

From Simply Wall St Dec 3, 2019

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sngx/soligenix/news/were-keeping-an-eye-on-soligenixs-nasdaqsngx-cash-burn-rate/">Read More...</a></div>

Soligenix completes patient enrollment late-stage CTCL study

From Seeking Alpha Dec 3, 2019

Soligenix (NASDAQ:SNGX) has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatmen

Imagine Owning Soligenix (NASDAQ:SNGX) And Trying To Stomach The 95% Share Price Drop

From Simply Wall St Nov 13, 2019

Soligenix, Inc. (NASDAQ:SNGX) shareholders should be happy to see the share price up 13% in the last month. But will that heal all the wounds inflicted over 5 years of<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sngx/soligenix/news/imagine-owning-soligenix-nasdaqsngx-and-trying-to-stomach-the-95-share-price-drop/">Read More...</a></div>

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy